The FDA's draft guidance is supposed to cut the cost and time-associated burden of biosimilar development, despite a mixed ...

With tighter regulations around biopharma manufacturing and the emergence of advanced therapies, cleanroom design is being ...

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

Eli Lilly will invest over $1.2bn into its manufacturing site in Puerto Rico, as it aims to assemble a robust supply chain ...

Dewpoint Therapeutics has received the US FDA's ODD for DPTX3186, a small-molecule condensate modulator for treating gastric ...

New research confirms Jungbunzlauer’s TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications.

Two of the world’s largest pharmaceutical companies, Pfizer (New York, US) and Roche (Basel, Switzerland), have unveiled more ...

Seres is set to receive up to $3.6m in further non-dilutive funding from the international non-profit partnership, CARB-X.

Elevara’s first-in-class asset ERV001, a CDK4/6 inhibitor, is set to enter Phase II testing as an add-on treatment in RA.

Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles.

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...